[1] Sung H, Ferlay J, Siegel RL, et al.Global Cancer Statistics2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study2017[J]. The Lancet, 2019, 394(10204): 1145-1158. [3] Ang SF, Ng ES, Li H, et al.The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma[J]. PLoS One, 2015, 10(4): e0118658. [4] Erstad DJ, Tanabe KK.Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493. [5] 周晓涵, 台蕴泽, 周娟. 术前预测肝细胞癌微血管侵犯的研究进展[J]. 中国肿瘤临床, 2022, 49(01): 47-52. [6] 李晨光, 窦文广, 付义彬, 等. CT技术联合CTCs、AFP对肝细胞癌微血管侵犯的预测价值[J]. 肝脏, 2021, 26(10): 1112-1114+1122. [7] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(02): 143-168. [8] 雷正清. 早期肝癌微血管侵犯的术前预测和对肝切除术切缘选择的影响[D]. 第二军医大学, 2016. [9] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies [J]. Sci Transl Med, 2014, 6(224): 224ra24. [10] Cai H, Zhang Y, Zhang H, et al.Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy[J]. J Surg Oncol, 2020, 121(6): 1007-1014. [11] 金赟, 李江涛. 肝癌细胞侵犯微血管的临床相关因素及分子标志物的研究进展[J]. 临床肝胆病杂志, 2013, 29(07): 550-553. [12] Eguchi S, Takatsuki M, Hidaka M, et al.Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from229 consecutive cases of curative liver resection[J]. World J Surg, 2010, 34(5): 1034-1038. [13] 谭君心, 符纯川, 李国华. 血小板淋巴细胞比值和肿瘤直径与肝细胞癌微血管侵犯的相关性[J]. 标记免疫分析与临床, 2020, 27(01): 48-52. [14] Li S, Zeng Q, Liang R, et al.Using Systemic Inflammatory Markers to Predict Microvascular Invasion Before Surgery in Patients With Hepatocellular Carcinoma[J]. Front Surg, 2022, 9: 833779. [15] Higuera M, Vargas-Accarino E, Torrens M, et al.Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management[J], Cancers (Basel), 2022, 14(16): 3875. |